MA53189B2 - Composition pharmaceutique destinée au traitement de l'anémie aplasique - Google Patents
Composition pharmaceutique destinée au traitement de l'anémie aplasiqueInfo
- Publication number
- MA53189B2 MA53189B2 MA53189A MA53189A MA53189B2 MA 53189 B2 MA53189 B2 MA 53189B2 MA 53189 A MA53189 A MA 53189A MA 53189 A MA53189 A MA 53189A MA 53189 B2 MA53189 B2 MA 53189B2
- Authority
- MA
- Morocco
- Prior art keywords
- pharmaceutical composition
- week
- treatment
- aplastic anemia
- romiplostim
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/196—Thrombopoietin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
La présente invention concerne une composition pharmaceutique destinée au traitement de l'anémie aplasique, ladite composition contenant du romiplostim en tant qu'ingrédient actif. Cette composition pharmaceutique est caractérisée en ce qu'elle est administrée par voie sous-cutanée une fois par semaine ; et en ce que pendant les quatre premières semaines suivant le début de l'administration, la quantité administrée de romiplostim est de 10 µg/kg/semaine, puis à partir de la cinquième semaine, la quantité de romiplostim est augmentée au-delà de 10 µg/kg/semaine, jusqu'à 20 µg/kg/semaine.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018202097 | 2018-10-26 | ||
| PCT/JP2019/041814 WO2020085467A1 (fr) | 2018-10-26 | 2019-10-25 | Composition pharmaceutique destinée au traitement de l'anémie aplasique |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53189A1 MA53189A1 (fr) | 2021-12-31 |
| MA53189B2 true MA53189B2 (fr) | 2023-09-27 |
Family
ID=70332110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53189A MA53189B2 (fr) | 2018-10-26 | 2019-10-25 | Composition pharmaceutique destinée au traitement de l'anémie aplasique |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20210379154A1 (fr) |
| EP (1) | EP3881856B1 (fr) |
| JP (2) | JPWO2020085467A1 (fr) |
| KR (1) | KR20210087045A (fr) |
| CN (1) | CN112888453A (fr) |
| AU (1) | AU2019364063B2 (fr) |
| BR (1) | BR112021007710A2 (fr) |
| CA (1) | CA3117477A1 (fr) |
| EA (1) | EA202191130A1 (fr) |
| ES (1) | ES2986153T3 (fr) |
| IL (1) | IL282470A (fr) |
| MA (1) | MA53189B2 (fr) |
| MX (1) | MX2021004551A (fr) |
| MY (1) | MY209352A (fr) |
| SG (1) | SG11202104199WA (fr) |
| TW (1) | TWI874330B (fr) |
| WO (1) | WO2020085467A1 (fr) |
| ZA (1) | ZA202102940B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114027263A (zh) * | 2021-12-01 | 2022-02-11 | 上海中医药大学 | 一种获得性再生障碍性贫血模型小鼠的生产方法 |
| WO2023149443A1 (fr) * | 2022-02-02 | 2023-08-10 | 国立大学法人 筑波大学 | Composition pharmaceutique pour la récupération des cellules sanguines après une greffe de sang de cordon |
| WO2024028744A1 (fr) * | 2022-08-01 | 2024-02-08 | Zydus Lifesciences Limited | Traitement de l'anémie aplasique (aa) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2319928T3 (da) * | 1998-10-23 | 2013-06-24 | Kirin Amgen Inc | Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet |
| AU2001280161A1 (en) * | 2000-08-24 | 2002-03-04 | Kirin Beer Kabushiki Kaisha | C-mpl ligand-containing medicinal compositions for increasing platelets and erythrocytes |
| JP6559185B2 (ja) | 2017-06-09 | 2019-08-14 | 株式会社カプコン | ゲームプログラムおよびゲーム装置 |
-
2019
- 2019-10-25 MX MX2021004551A patent/MX2021004551A/es unknown
- 2019-10-25 SG SG11202104199WA patent/SG11202104199WA/en unknown
- 2019-10-25 TW TW108138718A patent/TWI874330B/zh active
- 2019-10-25 WO PCT/JP2019/041814 patent/WO2020085467A1/fr not_active Ceased
- 2019-10-25 US US17/288,057 patent/US20210379154A1/en active Pending
- 2019-10-25 JP JP2020552613A patent/JPWO2020085467A1/ja active Pending
- 2019-10-25 EA EA202191130A patent/EA202191130A1/ru unknown
- 2019-10-25 KR KR1020217015296A patent/KR20210087045A/ko active Pending
- 2019-10-25 CA CA3117477A patent/CA3117477A1/fr active Pending
- 2019-10-25 ES ES19875343T patent/ES2986153T3/es active Active
- 2019-10-25 MA MA53189A patent/MA53189B2/fr unknown
- 2019-10-25 AU AU2019364063A patent/AU2019364063B2/en active Active
- 2019-10-25 MY MYPI2021002238A patent/MY209352A/en unknown
- 2019-10-25 EP EP19875343.6A patent/EP3881856B1/fr active Active
- 2019-10-25 BR BR112021007710-3A patent/BR112021007710A2/pt unknown
- 2019-10-25 CN CN201980069759.6A patent/CN112888453A/zh active Pending
-
2021
- 2021-04-20 IL IL282470A patent/IL282470A/en unknown
- 2021-04-30 ZA ZA2021/02940A patent/ZA202102940B/en unknown
-
2024
- 2024-06-19 JP JP2024098449A patent/JP2024123116A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2020085467A1 (ja) | 2021-09-16 |
| EP3881856A4 (fr) | 2022-06-29 |
| ES2986153T3 (es) | 2024-11-08 |
| MX2021004551A (es) | 2021-07-16 |
| MY209352A (en) | 2025-07-03 |
| WO2020085467A1 (fr) | 2020-04-30 |
| JP2024123116A (ja) | 2024-09-10 |
| MA53189A1 (fr) | 2021-12-31 |
| AU2019364063B2 (en) | 2025-04-17 |
| CN112888453A (zh) | 2021-06-01 |
| KR20210087045A (ko) | 2021-07-09 |
| BR112021007710A2 (pt) | 2021-08-10 |
| ZA202102940B (en) | 2022-10-26 |
| TWI874330B (zh) | 2025-03-01 |
| AU2019364063A1 (en) | 2021-06-10 |
| CA3117477A1 (fr) | 2020-04-30 |
| SG11202104199WA (en) | 2021-05-28 |
| IL282470A (en) | 2021-06-30 |
| EA202191130A1 (ru) | 2021-07-22 |
| EP3881856B1 (fr) | 2024-08-07 |
| US20210379154A1 (en) | 2021-12-09 |
| EP3881856A1 (fr) | 2021-09-22 |
| TW202021611A (zh) | 2020-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2019035057A3 (fr) | Exosomes pour administration spécifique à une cible et procédés de préparation et d'administration de ceux-ci | |
| MA53189A1 (fr) | Composition pharmaceutique destinée au traitement de l'anémie aplasique | |
| MA44206A (fr) | Comprimé orodispersible comprenant estetrol | |
| EA201991299A1 (ru) | Приготовление твердых циклодекстриновых комплексов для доставки офтальмологических активных фармацевтических ингредиентов | |
| EA202190115A1 (ru) | Пленочные составы, содержащие дексмедетомидин, и способы их получения | |
| US20160136231A1 (en) | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions | |
| MA33467B1 (fr) | Promédicaments comprenant un conjugué insuline-lieur | |
| SI9720035B (sl) | Substituirani benzensulfonamidni derivati kot predzdravila COX-2 inhibitorjev | |
| MA45972B1 (fr) | Unité posologique orodispersible contenant un composant d'estétrol | |
| MA44205B1 (fr) | Comprimé orodispersible comprenant estetrol | |
| MA34296B1 (fr) | Composition retard injectable antipsychotique | |
| MA54663A1 (fr) | Composition pharmaceutique aqueuse d'un anticorps anti-il17a et son utilisation | |
| MA46342B1 (fr) | Dérivés de chromane, d'isochromane et de dihydroisobenzofurane en tant que modulateurs allostériques négatifs de mglur2, compositions et leur utilisation | |
| MA43876B1 (fr) | Compositions pharmaceutiques et leur utilisations contre les maladies de surcharge lysosomale | |
| Lugo-Lugo et al. | Antinociceptive local activity of 4-allyl-1-hydroxy-2-methoxybenzene (eugenol) by the formalin test: an anti-inflammatory effect | |
| TWI250023B (en) | Pharmaceutical composition for itch treating agent | |
| MA45202B1 (fr) | Composition pharmaceutique comprenant un antagoniste du récepteur minéralocorticoïde et son utilisation | |
| MA39421A (fr) | Peptides dérivés de l'ezrine et compositions pharmaceutiques correspondantes | |
| FR3059236B1 (fr) | Extraits de plantes du genre tagetes et leurs utilisations | |
| JP6509244B2 (ja) | 水晶体硬化抑制剤 | |
| MA54940B1 (fr) | Dérivés d'acides aminés pour le traitement de maladies inflammatoires | |
| MA58507A1 (fr) | Composition pharmaceutique aqueuse de levilimab | |
| MA70850A1 (fr) | Composition pharmaceutique d'anticorps anti-cd20 et son utilisation | |
| WO2019027244A3 (fr) | Composition pour améliorer la prévention et le traitement du foie gras contenant un extrait d'amomum vilosum | |
| MA53521B1 (fr) | Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications |